Rover Diagnostics to occupy 15,763 SF move-in ready lab space; milestone underscores continued demand for turnkey life science environments
New York, NY– King Street Properties (“King Street”) and development partner, GFP real estate, today announced that Innolabs has reached full occupancy following the signing of a 15,763-square-foot lease with Rover Diagnostics. This lease highlights the continued demand for class A, move-in ready space. Rover Diagnostics will occupy a ground-floor, pre-built lab suite starting April 1.
“Achieving full occupancy at Innolabs is a reflection of the quality of our building and the continued need for flexible, ready-to-go lab environments,” said Ed Jaram, Senior Director at King Street. “Companies like Rover Diagnostics exemplify the type of innovative companies Innolabs was designed to support – those advancing critical work and seeking space that allows them to hit the ground running.”
“GFP is proud to welcome Rover Diagnostics to Innolabs,” said Tom Ortinau of GFP Real Estate. “There’s been a clear demand for quality lab space at a reasonable price point. It’s rewarding to see Innolabs fully occupied with innovative life science users that value a strong offering and the vibrancy and convenience of Long Island City.”
Innolabs has 267,000 square feet of modern lab space with choice amenities including a lobby café, event space and locker rooms in the vibrant and diverse community of Long Island City.
Rover Diagnostics is a leader in point-of-care PCR diagnostics, with a focus on advancing women’s health through accessible, rapid testing solutions. Their decision to locate at Innolabs highlights the growing demand for efficient, scalable lab infrastructure that supports next-generation healthcare innovation.
Mark Fasciano, CEO of Rover Diagnostics, said “As our Rover LightSpeed product moves from design into commercialization and manufacturing, Innolabs gives us exactly the platform we need to scale. The combination of high-quality lab space and proximity to public transit are critical to attracting the engineering and scientific talent that will bring rapid, lab-quality molecular diagnostics to the point of care.”
The transaction was brokered by Tom Burrus of JLL on behalf of Rover Diagnostics, and Bill Harvey and John Cahill of JLL on behalf of ownership.